Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2014
At a glance
- Drugs Gemifloxacin (Primary) ; Gemifloxacin (Primary)
- Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Urinary tract infections
- Focus Pharmacokinetics
- Sponsors LG Life Sciences
- 14 Jun 2013 New source identified and integrated (ClinicalTrials.gov record: NCT01879007).
- 05 Nov 2010 New trial record.